Partnership
We develop innovative technologies that overcome the barriers to nucleic acid delivery as your catalytic partner in enabling your genetic medicines
Partnering to Enable Next-Generation Genetic Medicines
NanoVation collaborates with pharmaceutical and biotechnology companies to overcome the delivery challenges that limit today’s genetic medicines. Our long-circulating lcLNP™ platform is designed to expand therapeutic possibilities by enabling potent, safe and scalable extrahepatic delivery.
We work alongside partners to design customized delivery solutions aligned with their target tissue, payload and program goals.
Every genetic drug has a cargo and delivery component, which require dedicated innovation on both.
We look forward to partnering with NanoVation, as the company’s differentiated delivery platform could help Novo Nordisk to advance genetic medicine candidates with curative potential.
18 September 2024 press release
Karina Thorn, PhD
Corporate Vice President, Head of Research, Global Nucleic Acid Therapies, Novo Nordisk
Collaborating with NanoVationtx™ has been a transformative experience for ME Therapeutics. It has allowed us to rapidly enter the exciting field of therapeutic mRNA development.
NanoVation’s cutting-edge expertise in LNP delivery technology has swiftly advanced our efforts to target myeloid cells with precision. Their innovative lcLNP™ platform ensures efficient and targeted delivery—which is crucial for our cancer therapeutics.
Combining our immuno-oncology specialization with NanoVation’s leadership in RNA delivery technology opens exciting new avenues for effective treatments.
Salim Dhanji, PhD
CEO & Co-Founder, ME Therapeutics
The need for mutation-proof vaccines was highlighted more than ever by the COVID pandemic. We at Baseimmune are tackling this problem by using AI to design next-generation antigens. We partnered with NanoVationtx™ to deliver these antigens using next-generation lipid nanoparticles, creating mRNA vaccines of the future.
Our company has high standards for the products and people we work with. Not only does NanoVationtx™ develop and deliver best-in-class technology, they share our vision to carry out the best science for the benefit of humankind.
Dr. Joshua Blight
CEO & Co-Founder, Baseimmune
Every genetic drug has a cargo and delivery component, which require dedicated innovation on both.
We look forward to partnering with NanoVation, as the company’s differentiated delivery platform could help Novo Nordisk to advance genetic medicine candidates with curative potential.
18 September 2024 press release
Karina Thorn, PhD
Corporate Vice President, Head of Research, Global Nucleic Acid Therapies, Novo Nordisk
Collaborating with NanoVationtx™ has been a transformative experience for ME Therapeutics. It has allowed us to rapidly enter the exciting field of therapeutic mRNA development.
NanoVation’s cutting-edge expertise in LNP delivery technology has swiftly advanced our efforts to target myeloid cells with precision. Their innovative lcLNP™ platform ensures efficient and targeted delivery—which is crucial for our cancer therapeutics.
Combining our immuno-oncology specialization with NanoVation’s leadership in RNA delivery technology opens exciting new avenues for effective treatments.
Salim Dhanji, PhD
CEO & Co-Founder, ME Therapeutics
The need for mutation-proof vaccines was highlighted more than ever by the COVID pandemic. We at Baseimmune are tackling this problem by using AI to design next-generation antigens. We partnered with NanoVationtx™ to deliver these antigens using next-generation lipid nanoparticles, creating mRNA vaccines of the future.
Our company has high standards for the products and people we work with. Not only does NanoVationtx™ develop and deliver best-in-class technology, they share our vision to carry out the best science for the benefit of humankind.
Dr. Joshua Blight
CEO & Co-Founder, Baseimmune
Our partnership approach
A Collaborative Model Designed Around Your Program
Every therapeutic program is different. Our partnership model is built to integrate with your workflows and accelerate progress from concept to lead candidate.
1
Collaborative planning
Development of workplan
based on your target product profile (TPP):
- Target tissue
- Administration route
- Nucleic payload
- Therapeutic application
2
Iterative design & development
Iterative development of LNPs
to identify and validate lead candidate with optimal efficacy & safety profile:
- Selection & optimization of next-generation lipids
- Design of RNA payload for improved activity at the target site
- Rational LNP design to streamline candidate selection
- Strategic pre-clinical proof-of-concept studies
3
Seamless tech transfer
Seamless technology transfer
for downstream scale-up & manufacturing:
- Safety studies
- Efficacy studies
Our pipeline
Filter by tissue
Filter by therapeutic area
Durable gene expression for treating genetic diseases
Adminstration route: i.v.
Platform technology: HepLNP
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene editing in extrahepatic tissues for treating genetic diseases
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: partnership
Gene editing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: Partnered
Gene expression for cancer immunotherapy
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression for healthy aging
Adminstration route: i.v.
Platform technology: combined
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression in tumors
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene silencing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: siRNA
Indication: not disclosed
Strategy: partnership
Gene silencing in skin and adipose tissues for genetic disease
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: siRNA
Indication: not disclosed
Strategy: partnership
mRNA vaccine for viral diseases
Adminstration route: i.m.
Platform technology: combined
Modality: mRNA
Indication: SARS & ASF
Strategy: partnership
YOU
have a therapeutic application in mind
WE
develop the best-in-class delivery technology for you
YOU
have a therapeutic application in mind
WE
develop the best-in-class delivery technology for you
Advancing Genetic Medicines Through Shared Innovation
Partners choose NanoVation because we combine deep scientific expertise with a flexible, collaborative mindset.
We deliver:
- Delivery solutions aligned to your therapeutic goals
- A credible, well-established scientific lineage in lipid nanoparticle innovation
- An IP position engineered to support commercialization
- An experienced team committed to clear communication and joint problem-solving
Our focus is simple:
Enable your genetic medicine to reach the right tissues, with the right potency and safety profile, to unlock its full potential.